As of this morning, at $2.09 per share, we have added Cryoport (NASDAQ:CYRX) to the Tailwinds Select Portfolio.
Cryoport is in the business of shipping medicines. Any biologic that needs to be cryogenically suspended until it is dosed into a recipient, needs a custom shipping platform for delivery. CYRX provides this service better than anyone else in the industry. This is validated by their being the exclusive cryogenically suspended shipping partner for DHL, FedEx and UPS.
As more of these medicines make their way through trials and into full prescription status, Cryoport stands to be the biggest winner. We believe this is a multi-year secular trend and are looking forward to owning CYRX for a long time and watching the company execute.
Disclosure: I am/we are long CYRX.